Article Details

Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed

Retrieved on: 2024-10-23 15:25:20

Tags for this article:

Click the tags to see associated articles and topics

Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed. View article details on hiswai:

Excerpt

On Wednesday, Rodman & Renshaw adjusted their stance on Alto Neuroscience (NYSE: ANRO), moving from a Buy rating to a Neutral position.

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo